TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00952094

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: KRN1493
Description: KRN1493 25mg tablet 2,3 or 4 tablets single oral administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: KRN1493
Description: KRN1493 25mg tablet 2,3 or 4 tablets single oral administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: KRN1493
Description: KRN1493 25mg tablet 2,3 or 4 tablets single oral administration
Study: NCT02183441

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BI 1356

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1356

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Study: NCT03225612

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mitralign Percutaneous Tricuspid Valve Annuloplasty System (PTVAS)
Description: Mitralign Percutaneous Tricuspid Valve Annuloplasty System (PTVAS) is delivered by a percutaneous transcatheter procedure. The Trialign PTVAS procedure utilizes catheters and wires to deliver up to two sets of pledgeted sutures across the tricuspid annulus near the septal/posterior and the posterior/anterior commissures. Each set of implants is pulled together to plicate the posterior tricuspid annulus.
Study: NCT04777227

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Debridement
Description: A debridement was completed using a scalpel and number 15 blade, a podiatry drill and a spherical podiatry burr.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Debridement
Description: A debridement was completed using a scalpel and number 15 blade, a podiatry drill and a spherical podiatry burr.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Needle insertion
Description: A 27-gauge needle on a 3 mL syringe was inserted at 10 to 15 degrees with the bevel facing up approaching from the IPK's right side
Study: NCT02677753

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Fluoroscopy
Study: NCT03457181

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: music
Description: effect of music on anxiety scores

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: operating room noise
Description: effect of operating room noise on anxiety scores
Study: NCT02851784

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: adoptive immunotherapy
Description: HCC (D ≤5 cm, fewer than three tumors) patients were treated with radical MWA and 4-6 courses of immunotherapy with CIK every year.The immunotherapy were started at 2 weeks, 4 weeks, 6 weeks, 10 weeks, 14 weeks, 18 weeks and then every 12 weeks after MWA. Peripheral blood mononuclear cells were differentiated into phenotypically confirmed DCs and effector cells. DC-CIK and CTL were injected into the abdominal cavity. CIK was infused intravenously.
Study: NCT04047303

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-90010
Description: CC-90010
Study: NCT03689452

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Platelet Rich Plasma
Description: Platelet Rich Plasma (PRP) is defined as an autologous concentration of human platelets that is 3 to 5 times greater than physiologic concentration of platelets in whole blood. Using the Eclipse PRP system, the participants PRP will be attained. The PRP will then be used as described in the arm/group description section.
Study: NCT02851784

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MWA
Description: ALL the HCC patients will be treated only by microwave ablation and then enter the follow-up

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MWA
Description: ALL the HCC patients will be treated only by microwave ablation and then enter the follow-up
Study: NCT02790437

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IdeS
Description: One dose of 0.25 mg/kg BW IdeS on study day 0. If negative crossmatch is not achieved, a second dose can be given within 2 days of the first infusion.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Kidney transplantation
Description: Performed following IdeS treatment
Study: NCT05760963

Intervention type: OTHER
Intervention: Collection of datas
Description: Analysis lumbar echographies results by Trident ans Shamrock techniques.~Costiform processes on T12 to L5 were spotted and noted. For Trident technique, quality of image, depth of lumbar plexus and presence of vessels were noted.~Shamrock technique was performed, the projection of C line (line obtained with a probe put on the iliac crest) was noted with the invisible ink pen. Then the probe was oriented cephalically (for line \>C) and caudally (line \<C). For each lines, quality of image, depth of lumbar plexus and presence of vessels were also noted.~The projections of C, \>C, \<C on the costiform processes were noted.
Study: NCT04082897

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab 25 MG/ML [Gazyva]
Description: Obinutuzumab will be administered from C1 to C8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab 60 MG/ML [Tecentriq]
Description: Atezolizumab will be administered iv from C1 to C18

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax Oral Tablet
Description: Venetoclax will be administered from day 15 cycle 1) until day 21 of cycle 35
Study: NCT02900131

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jaungo
Description: Participants in trial group 1 will apply Jaungo and placebo to the lesion once a day for three weeks. Participants in trial group 2 will apply Jaungo to the lesion twice a day for three weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jaungo
Description: Participants in trial group 1 will apply Jaungo and placebo to the lesion once a day for three weeks. Participants in trial group 2 will apply Jaungo to the lesion twice a day for three weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants in trial group 1 will apply Jaungo and placebo to the lesion once a day for three weeks. Participants in control group will apply placebo to the lesion twice a day for three weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants in trial group 1 will apply Jaungo and placebo to the lesion once a day for three weeks. Participants in control group will apply placebo to the lesion twice a day for three weeks.
Study: NCT04933591

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diosmin / Hesperidin
Description: Venoactive drugs are used for patients with varicose veins as a tool for alleviating symptoms
Study: NCT04974775

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood collection
Description: Sampling on admission to ICU (all patients)

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood collection
Description: Sampling on admission to ICU (all patients)
Study: NCT01194765

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Distance-based Cognitive Behavioural Therapy
Description: Participants will engage in cognitive behavioural therapy to treat high anxiety sensitivity. Treatment will be delivered over the telephone.
Study: NCT01169662

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vegetable/fruit juice
Description: 450ml active juice, 45ml no added sugar fruit squash (for flavour)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo juice
Description: 50 ml No Added Sugar fruit squash, 45 ml Pressed Apple Juice, 405ml with water.
Study: NCT00776828

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: cilostazol
Description: Pletaal (Otsuka Pharm.) 100mg bid for six months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cilostazol
Description: Pletaal (Otsuka Pharm.) 100mg bid for six months
Study: NCT04398030

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: coil-reinforced soft polymer indwelling cannula
Description: Insulin infusion set will be used for up to 7 days of continuous use or until failure

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: soft Teflon indwelling catheter
Description: Insulin infusion set will be used for up to 7 days of continuous use or until failure
Study: NCT02050646

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Salt Diet
Description: On Day 0, patients will be randomized to one of the two crossover liberal/low or low/liberal salt diet groups. Each subject will complete two controlled dietary phases: 10-days of low salt diet, a washout period of 3-days, and 10-days of liberal salt diet.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Salt Diet
Description: On Day 0, patients will be randomized to one of the two crossover liberal/low or low/liberal salt diet groups. Each subject will complete two controlled dietary phases: 10-days of low salt diet, a washout period of 3-days, and 10-days of liberal salt diet.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Liberal salt diet
Description: On Day 0, patients will be randomized to one of the two crossover liberal/low or low/liberal salt diet groups. Each subject will complete two controlled dietary phases: 10-days of low salt diet, a washout period of 3-days, and 10-days of liberal salt diet.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Liberal salt diet
Description: On Day 0, patients will be randomized to one of the two crossover liberal/low or low/liberal salt diet groups. Each subject will complete two controlled dietary phases: 10-days of low salt diet, a washout period of 3-days, and 10-days of liberal salt diet.
Study: NCT01907373

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: olmesartan medoxomil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olmesartan medoxomil+probenecid
Study: NCT01343329

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esmolol
Description: The Esmolol arm is defined as a 48-hour intravenous infusion of esmolol (Brevibloc 20mg/ml), which will be started on enrollment. The infusion rate will begin at 50 micrograms/kg/min and be adjusted to achieve heart rates between 80 and 100 beats/min with standard dosing regimens used in our Neuro intensive care unit. The infusion will be started at a rate of 0.05 milligrams/kg/min (50 micrograms/kg/min) for 5 minutes. After the 5 minutes of initial infusion, maintenance infusion may be continued at 0.05 mg/kg/min or increased stepwise (e.g. 0.1 mg/kg/min, 0.15 mg/kg/min to a maximum of 0.2 mg/kg/min) with each step being maintained for 4 or more minutes until the target heart rate is achieved.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propranolol
Description: The comparison arm will be comprised of oral propranolol, starting with 20mg PO every 6 hours prn (as needed) to reduce heart rate into target range. If 20mg is ineffective, the dose will be doubled at each dosing interval until an adequate dose is found, not to exceed 120mg four times daily. (ex: 20mg, 40mg, 80mg, 120mg)
Study: NCT05754970

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laser treated
Description: The second surgical stage was done after a healing period 12 ± 4 weeks (T1) where all the healing abutments were placed. Each healing abutment had repeated the two surfaces as twice follows: laser-treated/machined/ laser-treated/machined. Experimental healing abutment was removed after 30 ± 7 days, the same time as the soft tissue biopsy.~After the healing period (30 ± 7 days), before starting with the prosthetic restoration of the fixtures, an impression was taken of the small-diameter Has, and circular sections (diameter 5 mm) soft tissues around them were retrieved for analysis.
Study: NCT00937430

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bowel preparation (Fleets enema)
Description: Use of Bowel preparation (Fleets enema)
Study: NCT04196023

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium glycinate
Description: Oral administration of magnesium glycinate daily for 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Magnesium glycinate
Description: Oral administration of magnesium glycinate daily for 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Oral administration of identical-appearing placebo daily for 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration of identical-appearing placebo daily for 12 weeks
Study: NCT02135510

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metoclopramide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexamethason

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: palonosetron
Study: NCT01711645

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed onto aluminum phosphate
Description: 55 postpartum subjects receive a single intramuscular (IM) 0.5 mL dose of Adacel® (Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed).
Study: NCT01505374

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Study Technique
Description: One leg will receive the saphenous nerve block, at the level of the adductor canal (study technique). The block will be under ultrasound guidance. The local anesthetic will be 15 ml of 0.5% bupivacaine. All study patients, regardless of study arm will receive combined spinal epidural, with 3 ml of 0.5% bupivacaine as the spinal agent. Epidural local anesthetic, if needed, will consist of 2% lidocaine.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Study Technique
Description: One leg will receive the saphenous nerve block, at the level of the adductor canal (study technique). The block will be under ultrasound guidance. The local anesthetic will be 15 ml of 0.5% bupivacaine. All study patients, regardless of study arm will receive combined spinal epidural, with 3 ml of 0.5% bupivacaine as the spinal agent. Epidural local anesthetic, if needed, will consist of 2% lidocaine.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Control Technique
Description: The other leg will receive the femoral nerve block (control technique). The block will be under ultrasound guidance. The local anesthetic will be 30 ml of 0.25% bupivacaine. All study patients, regardless of study arm will receive combined spinal epidural, with 3 ml of 0.5% bupivacaine as the spinal agent. Epidural local anesthetic, if needed, will consist of 2% lidocaine.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Control Technique
Description: The other leg will receive the femoral nerve block (control technique). The block will be under ultrasound guidance. The local anesthetic will be 30 ml of 0.25% bupivacaine. All study patients, regardless of study arm will receive combined spinal epidural, with 3 ml of 0.5% bupivacaine as the spinal agent. Epidural local anesthetic, if needed, will consist of 2% lidocaine.
Study: NCT01456065

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Procure
Description: The IMP (Investigational Medical Product) consists of 1.3\*107 autologous, fully mature DCs, double loaded with TERT-mRNA and Survivin-peptide, diluted in 0.5 mL of a standard freezing solution, made up of 10% DMSO (Dimethyl sulfoxide), solved in a physiologic water solution of 5% glucose; provided in a 2 mL cryovial. 8 vial will be injected on weekly administration basis to the patient.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Procure
Description: The IMP consists of 1.3\*107 autologous, fully mature DCs, double loaded with TERT-mRNA and Survivin-peptide, diluted in 0.5 mL of a standard freezing solution, made up of 10% DMSO, solved in a physiologic water solution of 5% glucose; provided in a 2 mL cryovial, 8 vials will be injected into the patient on biweekly basis.
Study: NCT03809494

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HemaTrate™ Blood Filtration system
Description: Anticoagulated whole blood is loaded into the filtration system. During gravity filtration, the majority of platelets, plasma, and red blood cells pass through the filter into a filtrate bag. The TNCs are captured in the filter material and recovered via a back-flush with 0.9 % saline into a syringe.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Normal (0.9%) saline
Study: NCT03689452

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Preservative-free normal saline will be used as described in arm/group description section.
Study: NCT04604899

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: human retinal progenitor cells
Description: single intravitreal injection of 6.0 million human retinal progenitor cells (hRPC)
Study: NCT01399905

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carbidopa
Description: 75 mg of carbidopa per day versus 450 mg of carbidopa per day
Study: NCT03481699

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Incremental theory of personality
Description: The experimental intervention (originally developed by David S. Yeager and colleagues) teaches that individuals have the potential to change. It has three main parts. First, participants are asked to read scientific studies that provide evidence that behaviors are controlled by thoughts and feelings in brains, and that pathways in the brain have the potential to be changed under the right circumstances. Second, participants read several testimonials purportedly written by upperclassmen to bring credibility to the ITP. Finally, participants are asked to write their own version of such a narrative. This self-persuasive writing exercise has been shown to facilitate the internalization of the intervention message, building on a long line of research on cognitive dissonance.

Intervention type: OTHER
Group type: OTHER
Intervention: Educational Intervention
Description: The educational intervention involved scientific information about the human brain. It was designed to be parallel to the experimental intervention and, hence, it has also three main parts. First, participants are asked to read scientific information about the different areas of the brain and their specialties. Second, participants read several testimonials written by upperclassmen about their transition to high school and how their brains help them to adapt to the new space and all the physical differences of the building and the classes. Finally, participants are asked to write a letter to another student explaining the main things he or she has learned about the brain and thinks are important for adapting to the new physical environment in high school.
Study: NCT00932581

Intervention type: OTHER
Intervention: Bradykinesia UPDRS Motor Full Examination
Description: The first group will receive the full motor examination section in its original order.

Intervention type: OTHER
Intervention: Bradykinesia subscale of UPDRS Motor Examination
Description: The second group will receive the bradykinesia subscale first followed by the remainder of the motor examination section.
Study: NCT03977766

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chemotherapy prevalidation
Description: Outpatient Chemotherapy prevalidation will done~* with the help of a nurse, using the digital application, for cycle 2 and 3.~* by the patient alone, using the digital application, for cycle 4 and 5.
Study: NCT00206843

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Triage BNP Test
Study: NCT04527367

Intervention type: PROCEDURE
Intervention: Innovative medical technologies in invasive cardiology and cardiac surgery
Description: A follow-up study included the analysis of medical documentation of the Cardiosurgery and the Invasive Cardiology Departments to provided information on the duration and type of procedure performed.
Study: NCT04205721

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: School-based sexuality and HIV prevention scripted lesson plans
Description: The revised life orientation content and implementation approach were designed to address gaps in prior implementation of the sexuality and HIV education content. By using scripted lesson plans and training teachers to use these, it was thought that students would get better information and lessons on the material important for HIV prevention.
Study: NCT03004352

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: retrograde flow
Description: Two pneumatic cuffs were placed on the experimental arm, one on the lower forearm, and the other on the upper arm. Two cuffs were simultaneously inflated for 20 minutes. The distal cuff was inflated to 75 mm Hg and the proximal cuff was inflated to 40 mm Hg. The contralateral (control) arm was cuff free during this intervention.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: retrograde flow
Description: Two pneumatic cuffs were placed on the experimental arm, one on the lower forearm, and the other on the upper arm. Two cuffs were simultaneously inflated for 20 minutes. The distal cuff was inflated to 75 mm Hg and the proximal cuff was inflated to 40 mm Hg. The contralateral (control) arm was cuff free during this intervention.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: retrograde flow
Description: Two pneumatic cuffs were placed on the experimental arm, one on the lower forearm, and the other on the upper arm. Two cuffs were simultaneously inflated for 20 minutes. The distal cuff was inflated to 75 mm Hg and the proximal cuff was inflated to 40 mm Hg. The contralateral (control) arm was cuff free during this intervention.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: oxygen
Description: Supplemental 100% oxygen administered through a nasal cannula.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: oxygen
Description: Supplemental 100% oxygen administered through a nasal cannula.
Study: NCT00525005

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DOS (Docetaxel, Oxaliplatin and S-1)
Description: Docetaxel 52.5mg/m2 IV on D1 (diluted in 250 ml of normal saline over a 1 hour of each cycle before oxaliplatin) Oxaliplatin 105mg/m2 IV on D1 (diluted in 250 ml of 5% DW for 2 hours) S-1 80mg/m2/day on D1-14 (2 weeks of treatment followed by a 1-week rest period)
Study: NCT04314583

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention Control
Description: Participants in this group will be asked to recall 3 to 5 events from the prior day of the intervention and write, or if unable to write, speak about these events.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gratitude Journaling
Description: The gratitude journaling intervention involves participants writing or speaking 3-5 things for which they are grateful and focusing on these attributes. Participants will do this weekly for 12 weeks.
Study: NCT02360891

Intervention type: OTHER
Intervention: biomarkers (composite analysis)
Description: biological, imaging, electrophysiological and anatomopathological examinations

Intervention type: OTHER
Intervention: biomarkers (composite analysis)
Description: biological, imaging, electrophysiological and anatomopathological examinations

Intervention type: OTHER
Intervention: biomarkers (composite analysis)
Description: biological, imaging, electrophysiological and anatomopathological examinations
Study: NCT01855360

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tauroursodeoxycholic Acid and Doxycycline